Dry age-related macular degeneration (Dry AMD) is a chronic eye condition that causes gradual vision loss in the central field due to thinning of the macula. According to Shiyan Zhang et al., 2024, over 9 million people are expected to suffer from AMD-related vision loss by 2050. The growing focus on developing targeted dry age-related macular degeneration therapeutics, such as complement inhibitors, reflects rising demand for effective treatment options. According to the dry age-related macular degeneration pipeline analysis by Expert Market Research, the market is poised for significant growth in the coming years.
Major companies involved in the dry age-related macular degeneration pipeline analysis include Stealth BioTherapeutics Inc., Evergreen Therapeutics, Inc., and others.
Leading drugs currently in the pipeline include EG-301, GT005, PST-611, and others.
Pipeline growth for dry age-related macular degeneration is driven by advancements in complement pathway inhibitors, increased clinical trials targeting geographic atrophy, and rising investments in gene therapy-based treatments.
The Dry Age-Related Macular Degeneration Pipeline Analysis Report by Expert Market Research gives comprehensive insights into dry age-related macular degeneration therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dry age-related macular degeneration. The dry age-related macular degeneration report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dry age-related macular degeneration pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with dry age-related macular degeneration treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dry age-related macular degeneration.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Dry age-related macular degeneration (AMD) is a progressive eye condition that occurs when the macula, the central part of the retina, deteriorates over time, leading to central vision loss. It typically develops with aging due to the accumulation of drusen and degeneration of retinal cells.
Dry AMD treatment includes vitamin supplements, lifestyle changes, and FDA-approved therapies like SYFOVRE to slow lesion progression and preserve vision in patients with geographic atrophy. In February 2023, the U.S. Food and Drug Administration approved SYFOVRE (pegcetacoplan injection) by Apellis Pharmaceuticals for geographic atrophy secondary to dry AMD. The treatment, targeting the complement protein C3, significantly slowed lesion growth in the Phase 3 OAKS and DERBY trials.
According to Shiyan Zhang et al., 2024, over 9 million people globally are projected to suffer from vision loss due to age-related macular degeneration (AMD) by 2050, with women being disproportionately affected. As per Macular Degeneration Research, nearly 20 million adults in the United States have some form of AMD. In 2019, an estimated 18 million individuals aged 40 and above had early-stage AMD, while 1.49 million had advanced-stage disease. The global prevalence is expected to rise to 288 million by 2040. This rising incidence underscores the urgent need for innovative therapeutic development in the dry AMD drug pipeline.
This section of the report covers the analysis of dry age-related macular degeneration drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II at 52% covers a major share of the total dry age-related macular degeneration clinical trials. Phase II holds the largest share, followed by phase I with 33% and phase III with 14%. The strong presence of candidates in early and mid-development stages reflects robust innovation and research activity. These advancements are expected to significantly enhance treatment options and drive growth in the dry age-related macular degeneration market.
The drug molecule categories covered under the dry age-related macular degeneration pipeline analysis include small molecules, monoclonal antibodies, peptides, probiotics, gene therapies, polymers, and peptides. The dry age-related macular degeneration report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dry age-related macular degeneration. Small-molecule therapies are emerging as promising candidates in the dry age-related macular degeneration pipeline. For instance, GAL-101, a small molecule targeting misfolded amyloid-beta monomers, is currently being evaluated in a phase 2 trial. Administered as eye drops, it aims to reduce photoreceptor degeneration and slow the progression of geographic atrophy.
The EMR report for the dry age-related macular degeneration pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dry age-related macular degeneration therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dry age-related macular degeneration clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for dry age-related macular degeneration. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of dry age-related macular degeneration drug candidates.
EG-301, developed by Evergreen Therapeutics, Inc., is currently being evaluated in a Phase 2 clinical trial for patients with nonfocal geographic atrophy secondary to dry age-related macular degeneration (dAMD). This oral drug aims to enhance anti-inflammatory and antioxidant functions in retinal pigment epithelial cells. The study is assessing its safety and efficacy while EG-301 is being combined with AREDS2 supplements over six months.
GT005 is an investigational gene therapy sponsored by Gyroscope Therapeutics Limited, currently under evaluation in the Phase 2 ORACLE study. This long-term follow-up aims to assess the safety of GT005 in participants with geographic atrophy secondary to dry age-related macular degeneration who were treated in earlier trials. Delivered under the retina, GT005 is designed to increase CFI protein production to rebalance the overactive complement system and potentially preserve vision.
PST-611-CT1, sponsored by Eyevensys, is a first-in-class non-viral vectorized therapy currently undergoing a Phase 1 trial in patients over 50 with dry age-related macular degeneration (AMD). The study is evaluating the safety and tolerability of single ascending doses. PST-611 expresses human transferrin, a potent iron regulator, aiming to restore normal iron homeostasis, critical in slowing progression of geographic atrophy, a severe form of dry AMD.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Dry Age-Related Macular Degeneration Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for dry age-related macular degeneration. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into dry age-related macular degeneration collaborations, regulatory environments, and potential growth opportunities.
Age-Related Macular Degeneration Market Report and Forecast
Neovascular Age-Related Macular Degeneration Treatment Market Report and Forecast
Upto 25% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share